This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.
Provide voluntary, written, informed consent to participate in the study
Agree to provide a valid cell phone number and are willing to receive communications through text.
Healthy adults 45 - 79 years of age Can read and write English
Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly.
Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
Known food intolerances/allergy to any ingredients in the product
Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
Having had a significant cardiovascular event in the past 6 months
Single group
Qualia Senolytic
Dietary supplementQualia Senolytic manufactured by Qualia Life Science
Olink Target 48 Cytokine panel - TNF, IL1B, CXCL8, VEGFA
Biomarkers in blood, measured using the Olink Target 48 Cytokine panel: Tumor Necrosis Factor (TNF) Interleukin-1 Beta (IL1B) Interleukin-8 (CXCL8) Vascular Endothelial Growth Factor A (VEGFA)
Remaining biomarkers in the Olink Target 48 Cytokine panel
36-Item Short Form Health Survey (SF-36)
Frailty Index for Elders (FIFE)
Depression Anxiety Stress Scale-21 (DASS-21)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
